© 2020 MJH Life Sciences and Ophthalmology Times. All rights reserved.
Retina
Company seeks first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications
July 08, 2020
Patient enrollment for the NORSE 2 clinical trial has been completed, with safety and efficacy data expected to be reported in the third quarter of 2021.
TANGO: Helping target genes produce more protein
June 25, 2020
Overcoming protein deficiency in autosomal dominant optic atrophy
Fundus autofluorescence offers edge in white dot syndrome imaging
June 24, 2020
Subclinical lesions have been detected that are not apparent on other imaging platforms